This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Shaarawy, M. Articles by Lotfy, S. Search for Related Content PubMed PubMed Citation Articles by Shaarawy, M. Articles by Lotfy, S.

Insulin-Like Growth Factor Binding Protein-3: A Novel Biomarker for the Assessment of the Synthetic Capacity of Hepatocytes in Liver Cirrhosis

Department of Obstetrics & Gynecology (M.S.), Faculty of Medicine, Cairo University; Department of Medicine (M.A.F., B.A.M., S.L.), Ain Shams University, Cairo, Egypt

Address correspondence and requests for reprints to: Professor Mohamed Shaarawy, 21 El-Khalifa El-Maamoun, Roxy Building, Apt 701, Heliopolis, Cairo, Egypt.

The liver is the major source of circulating insulin-like growth factor binding protein-3 (IGFBP-3). Because the hepatic tissue is deranged in cirrhotic patients, we measured serum IGFBP-3 concentrations by two-site immunoradiometric assay in sera from 37 cirrhotic patients with different stages of hepatic dysfunction. These were compared with IGFBP-3 levels from 11 healthy controls. Serum IGFBP-3 levels in patients with chronic liver disease were significantly lower than those of the control group (P < 0.0005). The mean percent decrease in cases of early liver cirrhosis, cirrhosis without, and cirrhosis with ascites were 44%, 59%, and 82% respectively, indicating that serum IGFBP-3 levels decrease as the severity of hepatic dysfunction increases.

Moreover, the decrease was more pronounced in cases with hyperbilirubinemia, elevated serum transaminases, hypoalbuminemia, and prolonged prothrombin time. There was a significant positive correlation between serum IGFBP-3 and serum albumin, as well as a significant negative correlation between serum IGFBP-3 and prothrombin time. These results indicate the close correlation of IGFBP-3 levels to worsening of hepatic functions. The determination of serum IGFBP-3 level is a clinically useful marker for the assessment of the synthetic capacity of hepatocytes in cirrhotic patients and an early predictor of impending hepatic dysfunction as well. .